REPL ALERT: Securities Fraud Class Action Launched Against Replimune Group, Inc. - October 5, 2026 Deadline

Levi & Korsinsky announced that a securities fraud class action was filed against Replimune Group on behalf of investors who purchased REPL securities, seeking recovery for losses during the October 20, 2025 to April 10, 2026 class period. The complaint alleges Replimune failed to address FDA study design concerns in its BLA and submitted data from an early unplanned analysis of RP1-104 covering only 40 of 400 planned patients, making rejection of the BLA likely according to plaintiffs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.